Literature DB >> 9052734

In vitro and in vivo tumor growth suppression by HIV-1 Vpr.

S Mahalingam1, B MacDonald, K E Ugen, V Ayyavoo, M G Agadjanyan, W V Williams, D B Weiner.   

Abstract

We have previously reported that the human immunodeficiency virus type 1 (HIV-1) regulatory gene vpr induces differentiation of rhabdomyosarcoma (embryonal muscle tumor cell line) cells, an effect that is accompanied by reduced proliferative capacity of the transfected cells. In this report, we examine the effect of Vpr expression on several different tumor cell lines derived from unique lineages. These tumor cells display different patterns of modulated oncogenes including both ras and p53 mutations. Here we demonstrate that the growth of tumor cells in vitro and in vivo is arrested by the expression of HIV-1 Vpr. Expression of Vpr in several human tumor cell lines upon transfection resulted in an accumulation of cells in the G2/M phase of cell cycle with altered cellular morphology, including an increase in adherence, and growth arrest, consistent with a differentiated phenotype. Vpr expression in B78/H1 cells results in a marked reduction in colony formation in vitro and an associated reduction in melanin synthesis by the cells. Vpr-transfected melanoma cells inoculated into syngenic C57BL/6 mice showed a markedly reduced ability to form tumors in vivo. These results suggest that this retroviral regulatory gene has broad tumor suppressor effects, likely mediated by transcriptional regulation of the state of the host cell.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052734     DOI: 10.1089/dna.1997.16.137

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  9 in total

1.  Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation.

Authors:  S A Stewart; B Poon; J Y Song; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr.

Authors:  S Mahalingam; V Ayyavoo; M Patel; T Kieber-Emmons; D B Weiner
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

Review 3.  Using death to one's advantage: HIV modulation of apoptosis.

Authors:  T M Ross
Journal:  Leukemia       Date:  2001-03       Impact factor: 11.528

4.  The functionally conserved nucleoporins Nup124p from fission yeast and the human Nup153 mediate nuclear import and activity of the Tf1 retrotransposon and HIV-1 Vpr.

Authors:  Padmapriya Varadarajan; Sundarasamy Mahalingam; Peiyun Liu; Sarah Boon Hsi Ng; Sheetal Gandotra; Desmond Suresh Kumar Dorairajoo; David Balasundaram
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

5.  HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle.

Authors:  S Mahalingam; V Ayyavoo; M Patel; T Kieber-Emmons; G D Kao; R J Muschel; D B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

6.  Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2.

Authors:  Masakazu Kamata; Nobumoto Watanabe; Yoshiko Nagaoka; Irvin S Y Chen
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

7.  Anti-cancer effect of HIV-1 viral protein R on doxorubicin resistant neuroblastoma.

Authors:  Richard Y Zhao; Dong Liang; Ge Li; Christopher W Larrimore; Bernard L Mirkin
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

8.  Endogenous HIV-1 Vpr-mediated apoptosis and proteome alteration of human T-cell leukemia virus-1 transformed C8166 cells.

Authors:  Fang He; Yaoying Zeng; Xiaoping Wu; Yuhua Ji; Xianhui He; Thomas Andrus; Tuofu Zhu; Tong Wang
Journal:  Apoptosis       Date:  2009-10       Impact factor: 4.677

9.  Bioelectric applications for treatment of melanoma.

Authors:  Stephen J Beebe; Karl H Schoenbach; Richard Heller
Journal:  Cancers (Basel)       Date:  2010-09-27       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.